Objectives: The present study aims to investigate the changes in the expression levels of miR-675 and some selenoproteins (Sel K, Sel W, and Sel P) in patients with breast cancer, before and after radiotherapy.
Subjects And Methods: This study included 35 breast cancer patients who applied to the Department of Radiation Oncology for radiotherapy and 25 healthy female controls. miR-675 expressions were analyzed by using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Western blot was conducted to determine Sel K, Sel W, and Sel P expression levels. Biochemical parameters and complete blood count were analyzed by autoanalyzer system and automatic cell counter, respectively.
Results: Plasma Sel K protein expression levels were decreased in the after-radiotherapy group compared to the control and before-radiotherapy groups, but plasma miR-675 expression levels were lower in both before and after radiotherapy groups compared to the control group.
Conclusion: Our findings showed that miR-675 and Sel K expression levels changed after radiotherapy in breast cancer patients. These changes may have the potential to be biomarkers for the effectiveness of radiotherapy in breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09553002.2025.2473962 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the impact of RPN1 on tumorigenesis and immune response in cancer.
FASEB J
March 2025
Department of Oncology, The Central Hospital of Yongzhou, Yongzhou, Hunan, China.
The ribophorin family, including RPN1, has been associated with tumor progression, but its specific role in pan-cancer dynamics remains unclear. Using data from TCGA, GTEx, and Ualcan databases, we investigated the relationship of RPN1 with prognosis, genomic alterations, and epigenetic modifications across various cancers. Differential analysis revealed elevated RPN1 expression in multiple cancer types, indicating a potential prognostic value.
View Article and Find Full Text PDFPerioperative Trends in Distress Among Cancer Patients: A Systematic Review and Meta-Analysis.
Cancer Med
March 2025
Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.
Introduction: Distress is common among cancer patients, especially those undergoing surgery. However, no study has systematically analyzed distress trends in this population. The purpose of this study was to systematically review perioperative rates of distress, as well as differences across cancer types, in cancer patients undergoing surgical intervention.
View Article and Find Full Text PDFPotential biological roles of exosomal non-coding RNAs in breast cancer.
FASEB J
March 2025
Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin, China.
Breast cancer (BC) is one of the most common malignant tumors among women, accounting for 24.5% of all cancer cases and leading to 15.5% of cancer-related mortality.
View Article and Find Full Text PDFDesign, synthesis and biological evaluation of pyrazolo[3,4-]pyridine derivatives as dual CDK2/PIM1 inhibitors with potent anti-cancer activity and selectivity.
J Biomol Struct Dyn
March 2025
Applied Organic Chemistry Department, National Research Center, Dokki, Egypt.
The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-]pyridine derivatives (), confirmed spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay.
View Article and Find Full Text PDFCascade-Responsive Nanoprodrug Disrupts Immune-Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy.
Adv Healthc Mater
March 2025
Department of Ultrasound, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361000, P. R. China.
The abnormal tumor mechanical microenvironment due to specific cancer-associated fibroblasts (CAFs) subset and low tumor immunogenicity caused by inefficient conversion of active chemotherapeutic agents are two key obstacles that impede patients with desmoplastic tumors from achieving stable and complete immune responses. Herein, it is demonstrated that FAP-αCAFs-induced stromal stiffness accelerated tumor progression by precluding cytotoxic T lymphocytes. Subsequently, a cascade-responsive nanoprodrug capable of re-educating FAP-αCAFs and amplifying tumor immunogenicity for potentiated cancer mechanoimmunotherapy is ingeniously designed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!